Skip to main content
Premium Trial:

Request an Annual Quote

Celera Registration Statement Declared Effective; Split with ABI Expected on July 1

NEW YORK (GenomeWeb News) – Celera’s registration statement with the US Securities and Exchange Commission was declared effective yesterday by the regulatory body, clearing the way for Celera’s formal separation from sister company Applied Biosystems and parent firm Applera.
 
The split will take place at 12:01 a.m. EDT, on July 1, subject to certain conditions, including receipt of certain contents and listing of Celera’s stock on the Nasdaq, according to an Applera statement.
 
Celera had filed for the split in April. Under terms of the separation, shareholders of the Applera Group-Celera Group tracking stock will receive one share of new Celera Corporation shares for each share of the tracking stock they currently own. Upon completion of the deal, Celera will become an independent, publicly traded company.
 
Celera will trade on the Nasdaq under its current ticker symbol, CRA, and its current tracking stock will be delisted from the New York Stock Exchange.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.